Rates of Sustained Complete Renal Response with Long-term Use of Voclosporin in AURORA 2 (ACR Convergence 2024) - Sep 25, 2024 - Abstract #1545; Pres time: Nov 17, 2024; 10:30 AM - 12:30 PM; Location: Hall C; In Person; "SCRR is a novel endpoint that can be leveraged to illustrate disease trajectory of LN and treatment efficacy. Consistent with using CRR as an efficacy endpoint in AURORA 1, more VCS- than control-treated patients achieved SCRR, despite nearly 40% of the analyzed study population being ineligible due to the voluntary nature of AURORA 2 participation. The stringency and potential utility of this new endpoint require further exploration.This work was funded by Aurinia Pharmaceuticals Inc."
Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Ernie Yap1; Matt Truman2; Cynthia Auguste1; Vanessa Birardi3; Greg Keenan1
|